SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

Sonia Jangra(Icahn School of Medicine at Mount Sinai), Michael Schotsaert(Icahn School of Medicine at Mount Sinai), Ashley-Beathrese T. Salimbangon(Icahn School of Medicine at Mount Sinai), Lily Eaker(Icahn School of Medicine at Mount Sinai), Denise Jurczyszak(Icahn School of Medicine at Mount Sinai), Raveen Rathnasinghe(Seqirus (United States)), Daniel Floda(Icahn School of Medicine at Mount Sinai), Emily D. Ferreri(Icahn School of Medicine at Mount Sinai), Kayla T. Russo(Icahn School of Medicine at Mount Sinai), Miti Saksena(Icahn School of Medicine at Mount Sinai), Katherine F. Beach(Icahn School of Medicine at Mount Sinai), Daniel Stadlbauer(Icahn School of Medicine at Mount Sinai), Charles Gleason(Icahn School of Medicine at Mount Sinai), Komal Srivastava(Icahn School of Medicine at Mount Sinai), Rachel Chernet(SUNY Upstate Medical University), Giulio Kleiner(Icahn School of Medicine at Mount Sinai), Hala Alshammary(Icahn School of Medicine at Mount Sinai), Wanni A. Mendez(Icahn School of Medicine at Mount Sinai), Julia C. Matthews(Icahn School of Medicine at Mount Sinai), Luis Martínez‐Sobrido(Texas Biomedical Research Institute), Levy A. Sominsky(Icahn School of Medicine at Mount Sinai), Florian Krammer(Icahn School of Medicine at Mount Sinai), Angela A. Amoako(Icahn School of Medicine at Mount Sinai), Mahmoud Awawda(Icahn School of Medicine at Mount Sinai), Lubbertus C. F. Mulder(Icahn School of Medicine at Mount Sinai), Viviana Simon(Icahn School of Medicine at Mount Sinai), Chengjin Ye(Texas Biomedical Research Institute), Adolfo Garcı́a-Sastre(Icahn School of Medicine at Mount Sinai), Amber S. Shin(Icahn School of Medicine at Mount Sinai), Maria C. Bermúdez‐González(Icahn School of Medicine at Mount Sinai)
The Lancet Microbe
April 7, 2021
Cited by 435


Related Papers